



Universiteit
Leiden
The Netherlands

Comparison of the mid-term outcomes of banded and non-banded sleeve gastrectomy: safety, food tolerance, and weight regain

Hany, M.; Sabry, A.; Torensma, B.; Ahmed, K.; Refaie, M.; Zidan, A.; ... ; Mourad, M.

Citation

Hany, M., Sabry, A., Torensma, B., Ahmed, K., Refaie, M., Zidan, A., ... Mourad, M. (2022). Comparison of the mid-term outcomes of banded and non-banded sleeve gastrectomy: safety, food tolerance, and weight regain. *Surgical Endoscopy*, 36, 9146-9155. doi:10.1007/s00464-022-09395-4

Version: Publisher's Version
License: [Creative Commons CC BY 4.0 license](https://creativecommons.org/licenses/by/4.0/)
Downloaded from: <https://hdl.handle.net/1887/3479842>

Note: To cite this publication please use the final published version (if applicable).



Comparison of the mid-term outcomes of banded and non-banded sleeve gastrectomy: safety, food tolerance, and weight regain

Mohamed Hany^{1,3} · Ahmed Sabry² · Bart Torensma⁴ · Khaled Ahmed² · Mostafa Refaie² · Ahmed Zidan¹ · Ann Samy Shafiq Agayby¹ · Mohamed Ibrahim¹ · Mohamed Mourad²

Received: 22 February 2022 / Accepted: 6 June 2022 / Published online: 28 June 2022
© The Author(s) 2022

Abstract

Background Long-term weight regain (WR) after sleeve gastrectomy (SG) is a major challenge. Laparoscopic banded SG (BSG) was introduced to overcome pouch dilation and, consequently, WR; however, its mid- and long-term outcomes have not been sufficiently demonstrated.

Objective This study retrospectively evaluated the mid-term weight loss efficacy and morbidity over at least a 4-year follow-up after laparoscopic banded SG using a MiniMizer Gastric Ring® and laparoscopic non-banded SG.

Method The data of 1586 bariatric surgeries were retrospectively evaluated. To ensure homogeneity in our study cohort, propensity score matching (PSM) was performed.

Results The final cohort comprised 1392 patients: the non-banded SG ($n = 1260$) and BSG ($n = 132$) groups. In our matched cohort (SG, $n = 655$ and BSG, $n = 132$), WR was noted in 4 (3.0%) and 71 (10.8%) patients in the BSG and SG groups, respectively. Gastric band erosion or slippage was not noted in the BSG cohort. The levels of cholesterol and triglyceride were similar in the two groups. Postoperative glycemic control was significantly reduced in the BSG group.

Conclusion Although the percentage of weight loss achieved in the BSG group was low in the first year postoperatively, the mid-term (sustained) weight loss associated with BSG was superior to that associated with non-banded SG. BSG is a safe procedure with no significant mid-term band-related morbidity; its impact on the resolution of comorbidities is equivalent and perhaps superior to SG.

Keywords Banded- and non-banded sleeve · Food tolerance · Weight regain · Safety · Bariatric surgery

Sleeve gastrectomy (SG) is one of the most common bariatric procedures performed nowadays [1]. SG is popular because of its safety, simplicity, low postoperative morbidity, and ability to be converted [2]. Despite its proven efficacy, long-term weight regain (WR) after SG is one of the major disadvantages of SG. The percentage of excess weight loss

(%EWL) decreased significantly at 5 years postoperatively [3]. In a meta-analysis of nine cohort studies, the recidivism rate was 14–37% after 7 years of follow-up; the authors of this meta-analysis defined recidivism as obtaining a % EWL of < 50% after having an initial %EWL of > 50% [4]. The theories for WR include non-compliance to post SG regimen by the patients and anatomical factors such as gastric pouch dilation [4].

The silastic ring was used to prevent gastric pouch dilation in patients that underwent Roux-en-Y gastric bypass (RYGB) and banded SG (BSG) [5–7]. In 2008, Greenstein and Jacobs applied the gastric band in post SG cases with insufficient weight loss and dilated gastric pouch. The resulting weight loss was encouraging [8]. In the same year, Arceo-Olaiz et al. used the synthetic band during laparoscopic Roux-en-Y gastric bypass with equivalent weight-loss rates after 2 years [9].

✉ Mohamed Hany
dr.mhany@gmail.com

¹ Department of Surgery, Medical Research Institute, Alexandria University, 165 Horreya Avenue, Hadara 21561, Alexandria, Egypt

² Department of Surgery, Faculty of Medicine, Alexandria University, Alexandria, Egypt

³ Consultant of Bariatric Surgery at Madina Women's Hospital (IFSO Center of Excellence), Alexandria, Egypt

⁴ Clinical Epidemiologist, Leiden University Medical Center (LUMC), Leiden, The Netherlands

Long-term morbidity was the main complication associated with laparoscopic adjustable gastric banding (LAGB) [10]. Complications such as gastric band erosion, oral intolerance, band slippage, gut obstruction, and WR have been reported [11]. After that, LAGB lost its popularity due to poor long-term outcomes, especially insufficient weight loss (IWL) [5].

Laparoscopic BSG was introduced to overcome the pouch dilation and, consequently, WR; however, the mid- and long-term outcomes of BSG on its mid- or long-term impact on food tolerance by patients have not been sufficiently reported. Therefore, this study aims to assess retrospectively (over a 4-year follow-up period) the mid-term effects of laparoscopic BSG on weight loss and co-morbidities resolution and food tolerance using a MiniMizer Gastric Ring® (Bariatric Solutions International, Switzerland) and compare them to those of laparoscopic non-banded SG.

Materials and methods

Study design

This study was a retrospective cohort study comparing the perioperative and mid-term outcomes of banded and non-banded SG. The study was approved by the Institutional Review Board and conformed to the precepts of the 1975 Declaration of Helsinki.

Study population

The study population consisted of adult patients who underwent laparoscopic banded or non-banded SG for extreme obesity at the Medical Research Institute Hospital and Alexandria University Main Hospital between January 2016 and December 2017.

Eligibility for bariatric or metabolic surgery

The surgical indication was extreme [body mass index (BMI) > 40 kg/m²] or severe (BMI 35–40 kg/m²) obesity with comorbidities interfering with the quality of life, after evaluation by a multidisciplinary team, according to the National Institutes of Health recommendations [12, 13]. All the patients scheduled for SG were offered the option of having BSG or SG, and the decision was made by the patients after the advantages and disadvantages of the procedures were explained, including the cost, unavailability of long-term outcomes, and psychological effects. All the patients provided informed consent to undergo BSG or SG and anonymously use their data for research.

Surgical technique

SG was performed as previously described [6]. Two teams performed the SGs, and all the BSGs were performed by the same surgeon in a multi-disciplinary team setting. Approximately 70–80% of the gastric volume was resected using a 40 French bougie. For BSG, perigastric dissection was performed 4–5 cm from the gastroesophageal junction, and a size 7.5 (1.75 cm internal diameter) MiniMizer Gastric Ring® (Bariatric Solutions International, Switzerland) was placed loosely around the pouch.

Non-absorbable sutures were used to fix the ring to the stomach passing through the built-in holes in the ring. Concomitant operative procedures included crural repair when hiatal hernia was present, using unidirectional barbed 2/0 V-Loc non-absorbable sutures (Covidien, Mansfield, MA, USA), and cholecystectomy using the same ports without adding extra ports.

Follow-up after surgery

All the patients were regularly followed-up at the outpatient clinic over four years (at 6 months and 1-, 2-, 3-, and 4-years postoperatively). The following data were collected at each visit: the body weight, BMI, postoperative hemoglobin, fasting plasma glucose, cholesterol, triglycerides levels, serum albumin, ferritin, calcium, vitamins D3 and B12, and renal and liver functions. Routine endoscopy was performed for all the patients 1 year postoperatively. Additional endoscopies were performed depending on the patients' symptoms.

Data retrieval from records and definitions

The data were retrieved, and the preoperative baseline characteristics were collected, including the age, sex, body weight, height, BMI, operation time, symptoms of gastroesophageal reflux disease (GERD), endoscopic findings of GERD, hiatal hernia, and gallstones detected by ultrasonography and comorbidities (including diabetes mellitus, hypercholesterolemia, hyperlipidemia, ischemic heart disease, essential hypertension, impaired renal function, obstructive sleep apnea, and history of upper abdominal surgery).

Data on BMI, EWL, total weight loss (TWL), WR, amelioration of comorbidities, and serial laboratory investigations, including HbA1c, fasting blood glucose level, hemoglobin, calcium, vitamin D3, and vitamin B12, were obtained at each visit.

Food tolerance was assessed for all the patients at the first and fourth-year follow-up visits using a one-page questionnaire (with the scores ranging between 1 and 27) with questions on overall alimentation satisfaction, meal timing

through the day, and several food types tolerability, and vomiting and regurgitation events. The higher the score, the better the food tolerance [14].

The mid-term morbidity was assessed using postoperative symptoms of GERD, food intolerance, constriction at the incisura or band site, and band erosion or slippage. Additionally, the conversion rate to other bariatric surgeries due to IWL, WR, or mid-term complications was determined.

The percentage total weight loss and %EWL were calculated using the formulae: (weight loss/the initial weight) and (weight loss/baseline excess weight) \times 100, respectively, where weight loss = preoperative weight – initial weight \times 100, baseline excess weight = initial weight – ideal weight (X), and $X = 23 \text{ kg/m}^2$. X was calculated using an ideal BMI (23 kg/m^2) [15] $\text{IWL} = \text{EWL}$ of $< 50\%$. [16] Insufficient weight loss was defined as $\text{EWL} < 50\%$ after 1 year from surgery [17]. WR was defined as 10% regain of the nadir weight at the last follow-up visit [18, 19].

Endoscopic grading for reflux esophagitis was done using the Los Angeles Classification of Gastroesophageal Reflux. The Dindo-Clavien score was used to assess the 30-day-postoperative morbidity [20]. A score of ≥ 3 indicates severe postoperative morbidity.

Statistical analysis

Continuous variables were presented as median and interquartile ranges and compared using the Mann–Whitney *U* test, whereas categorical variables were presented as numeric proportions and compared using the χ^2 test, Fisher's exact test, or Monte Carlo test [21].

To minimize the differences in the baseline characteristics of the patients between the groups, propensity score matching (PSM) was performed. The covariates included in the propensity score were age, sex, BMI, essential hypertension, diabetes mellitus, obstructive sleep apnea, dyslipidemia, osteoarthritis, preoperative gastroesophageal reflux, presence of hiatal hernia, gallstones, cardiac disease, psychological disorders, thrombo-vascular complications, neoplasm, alcohol intake, and smoking status. The matching algorithm was used according to the nearest neighbor method, with a 1:5 ratio (without replacement) and a caliper width of 0.2. The balance between the two groups was assessed using the standardized mean difference for baseline characteristics [22].

The outcome variables were compared in the two matched groups using the logistic regression analysis with a robust variance estimator. Repeated measure analysis of variance was used to measure variable changes. The mid-term outcome was assessed by calculating the time to successful weight loss using the Kaplan–Meier method, and a comparison was performed using the stratified log-rank test. Univariable logistic regression analysis was performed to identify

the impact of BSG (successful EWL and WR) compared with SG. All the calculations were performed using IBM Corp. Released 2017. IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp, and R software version 3.3.3 (R Foundation for statistical computing). All the tests were two-tailed, and statistical significance was established at $p < 0.05$. Graphs were drawn using GraphPad Prism 8.0.1 software.

Results

Patient demographics

The data of 1586 bariatric surgeries performed between January 2016 and December 2017 at the Medical Research Institute Hospital and Alexandria University Main Hospital were collected. Furthermore, 174 patients who underwent surgeries other than SG and redo surgeries were excluded. Twenty patients with incomplete follow-up records were excluded. The final cohort comprised 1392 patients who were divided into the non-banded SG ($n = 1260$) and BSG groups ($n = 132$) (Fig. 1).

The baseline characteristics were compared between the two groups. No significant difference was noted in the demographic features (such as age and sex) and anthropometric measures (including waist circumference, height, weight, and BMI) between the groups. Moreover, the preoperative comorbidities, including essential hypertension, diabetes mellitus, obstructive sleep apnea, dyslipidemia, osteoarthritis, preoperative gastroesophageal reflux, the presence of hiatal hernia, gallstones, menstrual abnormality, cardiac diseases, psychological disorders, thrombo-vascular complications, neoplasm, alcohol intake, or smoking, were similar in the groups. None of the patients in our cohort had positive serology markers for hepatitis B or C (Table 1).

To ensure homogeneity in our study cohort, PSM was performed. After PSM, 605 patients in the SG group were unmatched and excluded from the study cohort, and the remaining 658 patients and all the patients in the BSG group were matched and included in the study.

After that, all the baseline characteristics of the matched groups were compared. All the variables were equally distributed in the study groups, with no significant differences. In addition, the standardized mean difference (SMD) was < 0.1 for all the variables (Table 2).

The operative time was equivalent in both cohorts (Table 3). The three cases of gastric leakage were managed by stent insertion with favorable outcomes. The 30-day-postoperative severe morbidity rates were comparable in the study groups ($p = 1.0$). GERD was encountered in 109 patients (16.6%) in the SG group vs. 19 patients (14.4%) in the BSG group, with no significant difference ($p = 0.552$).




Fig. 1 Study flow chart. *BSG* banded sleeve gastrectomy, *IFSO* International Federation for the Surgery of Obesity and Metabolic Disorders, *PSM* propensity score matching, *SG* non-banded sleeve gastrectomy

Furthermore, 111 patients (16.8%) in the SG group required conversion to RYGB. For the indications for conversion were weight regain in 51 (7.75%), GERD in 43 (6.5%), and GERD with WR in 17 (2.6%) patients. No patient needed conversion in the BSG group throughout the 4-year follow-up period ($p < 0.0001$). It is noteworthy that in the BSG group, 25 patients presented with esophagitis preoperatively, and the postoperative routine endoscopy in 21 of them (84%) showed regression of the reflux.

No case of gastric band erosion or slippage was noted in our BSG cohort. Three patients (2.3%) in the BSG group experienced solid dysphagia and reflux symptoms during the follow-up period. Endoscopy revealed constriction at the band site that required a few endoscopic pneumatic balloon dilation sessions with satisfactory results.

Regarding the impact on the comorbidities, at the 4-year follow-up visit, the cholesterol and triglyceride levels in the SG and BSG groups were equivalent with $p = 0.713$ and 0.969 , respectively. In addition, the fasting blood sugar (FBS) levels were not significantly different between the study groups (Table 4).

Analysis of the 137 patients with the comorbidity diabetes in our matched cohorts showed that although the patients in the BSG group had a higher mean preoperative FBS level (149 mg/dl versus 104 mg/dl in the BSG and SG groups, ($p < 0.001$), the postoperative glycemic control was equivalent between the groups (postoperative FBS level of 94 mg/dl in the groups,

($p = 0.995$), but significant difference before and after surgery in both groups. ($p < 0.0001$) (Fig. 2).

The median score for food tolerance after 1 year postoperatively of the groups was the same (21). On the contrary, the median score for food tolerance at the end of the 4th year postoperatively was 24 for the SG group. It was significantly higher than that of the BSG group, which remained unchanged at 21 ($p < 0.0001$) (Fig. 3). During the index procedure, a concomitant cholecystectomy was performed 59 (9.0%) and 14 (10.6%) times, and concomitant hiatal hernia repair was performed 34 (5.2%) and 7 (5.3%) in SG and BSG groups, respectively (Table 3).

Matched cohort

In the matched cohort, 4 cases (3.0%) of WR were noted in the BSG group and 71 (10.8%) in the SG group, with a significant difference ($p < 0.001$). At the 1-, 2-, 3- and 4-year follow-up visits, all the patients in the BSG group successful reached the EWL of $> 50\%$, whereas the %IWL rates in the SG group were 3.1%, 2.3%, 3.7%, and 5.3%, respectively, with no significant difference between the groups. No single case in the BSG group has reached a nadir weight reflecting insufficient weight loss ($< 50\%$ EWL). Meanwhile, nine patients in the SG group have reached nadir reflecting insufficient weight loss, only one had WR, while the remaining eight patients did not.

The rate of successful weight loss (EWL $\geq 50\%$) at 6 months was higher in the SG group than in the BSG group

Table 1 Baseline characteristics before propensity score matching

	SG ^a N=1260	BSG ^b N=132	p value
<i>Demography</i>			
Sex (M/F)	321/939	28/104	0.282
Age (years)	34.0 (28.0–42.0)	34.5 (27.0–40.0)	0.492
<i>Comorbidities</i>			
HTN ^c	381 (30.2%)	40 (30.3%)	0.988
DM ^d	218 (17.3%)	24 (18.2%)	0.800
OSA ^e	160 (12.7%)	19 (14.4%)	0.580
Dyslipidemia	379 (30.1%)	40 (30.3%)	0.957
Osteoarthritis	322 (25.6%)	34 (25.8%)	0.960
Cardiac disease	80 (6.3%)	8 (6.1%)	0.897
Psychological disorders	162 (12.9%)	16 (12.1%)	0.810
Vascular diseases	191 (15.2%)	20 (15.2%)	0.998
DVT ^f , PE ^g	20 (1.6%)	2 (1.5%)	1.000*
Neoplasm	23 (1.8%)	2 (1.5%)	1.000*
Gallstones	129 (10.2%)	13 (9.8%)	1.000
Smoking	445 (35.3%)	47 (35.6%)	0.947
Alcohol	18 (1.4%)	2 (1.5%)	1.000*
<i>Preoperative endoscopic assessment</i>			
Hiatal hernia	78 (6.2%)	7 (5.3%)	0.685
Esophagitis	254 (20.2%)	25 (18.9%)	0.739
<i>Anthropometric measures</i>			
Waist (cm)	115.0 (108.0–132.0)	116.0 (108.0–132.0)	0.902
Height (m)	1.67 (1.60–1.74)	1.67 (1.59–1.74)	0.874
Weight (kg)	130.0 (115.0–146.0)	130.0 (115.0–145.9)	0.916
BMI ^h	47.5 (42.7–52.1)	47.4 (42.8–52.3)	0.985
<i>Parameters of glycemic control</i>			
FBS ⁱ	96 (85–108)	96 (86–106)	0.844
HbA1c ^j	8.0 (7.0–9.0)	8.0 (7.0–9.0)	0.958

Categorical variables are expressed in counts (percentages). Continuous variables are expressed in median values (interquartile range)

^aVariables used in the propensity score matching

^bFisher's exact test

^aBG Sleeve gastrectomy,

^bBSG Banded sleeve gastrectomy

^cHTN essential hypertension

^dDM diabetes mellitus

^eOSA obstructive sleep apnea

^fDVT deep vein thrombosis

^gPE: ^hBMI: body mass index

ⁱFBS fasting blood sugar

^jHbA1c glycated hemoglobin, HCV hepatitis C virus, PS propensity score

and gradually increased till 4 years postoperatively. Meanwhile, all the patients in the BSG group had reached successful weight loss at the 1-year follow-up visit ($p=0.003$).

The EWL% at 6 months was significantly lower in the BSG group than in the SG group ($p=0.037$), the EWL% rates were not significantly different between the study groups at the 1-, 2-, and 3-year follow-up visits (Fig. 4).

Discussion

This is one of the largest studies to evaluate and compare the outcomes of BSG with non-BSG over a mid-term follow-up period of 4 years in all the included patients. In addition, this study cohort comprised two identical study groups with comparable baseline characteristics using

Table 2 Baseline characteristics after propensity score matching

	SG ^a group (n = 655)	BSG ^b group (n = 132)	p	SMD ^c Before	SMD After
<i>Demography</i>					
Sex M/F ^a	135/523	28/104	0.857	−0.104	0.030
Age (year) ^a	30.0 (24.0–39.0)	34.5 (27.0–40.0)	0.821	−0.111	0.028
<i>Comorbidities</i>					
HTN ^{d, a}	190 (28.9%)	40 (30.3%)	0.753	0.001	0.026
DM ^{e, a}	113 (17.3%)	24 (18.2%)	0.797	0.023	0.020
OSA ^{f, a}	93 (14.1%)	19 (14.4%)	0.938	0.048	0.034
Dyslipidemia ^a	202 (30.7%)	40 (30.3%)	0.928	0.005	0.021
Osteoarthritis ^a	163 (24.8%)	34 (25.8%)	0.811	0.005	0.078
Cardiac disease ^a	46 (7.0%)	8 (6.1%)	0.699	−0.012	−0.013
Psychological disorders ^a	82 (12.5%)	16 (12.1%)	0.914	−0.022	0.018
Vascular diseases ^a	106 (16.1%)	20 (15.2%)	0.784	<0.001	−0.007
Thromboembolic complication (DVT ^g , PE ^h) ^a	11 (1.7%)	2 (1.5%)	1.000 ^b	−0.006	−0.025
Neoplasm ^a	14 (2.1%)	2 (1.5%)	1.000 ^b	−0.025	0.012
Gallstones ^a	59 (9.0%)	13 (9.8%)	0.742	−0.013	0.030
Smoking ^a	214 (32.5%)	47 (35.6%)	0.492	0.006	−0.020
Alcohol ^a	11 (1.7%)	2 (1.5%)	1.000 ^b	0.007	−0.025
<i>Preoperative endoscopic assessment</i>					
Esophagitis ^a	130 (19.8%)	25 (18.9%)	0.829	−0.031	0.020
Hiatal hernia ^a	35 (5.3%)	7 (5.3%)	0.991	−0.039	0.007
<i>Anthropometric measures</i>					
Waist	115.0 (108.0–131.3)	116.0 (108.0–132.0)	0.882	0.016	0.011
Height ‘m’	1.7 (1.6–1.7)	1.7 (1.6–1.7)	0.950	−0.010	0.003
Weight ‘kg’	129 (113–146)	130 (115–146)	0.816	0.001	0.019
BMI ^{i a}	47.2 (42.5–52.1)	47.4 (42.8–52.3)	0.725	0.008	0.025
<i>Parameters of glycemic control</i>					
FBS ^j	96.0 (86.0–108.0)	96.0 (85.0–108.0)	0.757	0.010	0.019
HbA1c ^k	8.0 (7.0–9.0)	8.0 (7.0–9.0)	0.945	−0.001	−0.019

Categorical variables are expressed in counts (percentages). Continuous variables are expressed in median values (interquartile range)

^aVariables used in the propensity score matching

^bFisher’s exact test

^aSG Sleeve gastrectomy ^bBSG Banded sleeve gastrectomy ^cSMD standardized mean difference, ^dHTN essential hypertension, ^eDM diabetes mellitus, ^fOSA obstructive sleep apnea, ^gDVT deep vein thrombosis, ^hPE: ⁱBMI: body mass index, ^jFBS fasting blood sugar, ^kHbA1c glycated hemoglobin, ^hHCV hepatitis C virus, ^{PS} propensity score

PSM. We achieved an SMD of < 0.1 for all the baseline variables in the groups.

Laparoscopic SG was initially introduced as a step in a two-stage bariatric surgery in patients with extreme obesity to minimize the surgical risk. The short-term outcomes of SG, in terms of EWL, resolution of comorbidities, and safety, with low rates of postoperative complications, are excellent [3]. The EWL% was 86% at 1 year postoperatively. There was marked resolution of hypertension, obstructive sleep apnea (99%), and diabetes mellitus (957%) in > 90% of the patients [3]. After restrictive surgeries, including SG, long-term (sustained) weight control is still a challenge [23–25].

In our study, WR at 4 years postoperatively was 3.0% in the BSG group and 10.8% in the SG group ($p < 0.001$). This finding supports the suggested role of BSG in overcoming the disadvantage of non-banded SG (that is, sustained EWL rates). Moreover, at the end of the first year postoperatively, 100% of the patients in the BSG group had achieved successful weight loss, which was maintained till the end of the 4-year follow-up period. Meanwhile, in the non-banded SG group, an increasing trend in IWL was noted starting from the end of the second postoperative year. This explained the importance of the ring in preventing gastric dilation, which is believed to be responsible for WR following non-banded SG. The other possible mechanism includes the additive

Table 3 Comparison of operative and postoperative data between both the study groups

	SG ^a group (n = 655)	BSG ^b group (n = 132)	p
Operative time (min) [†]	41.63 ± 7.45	41.82 ± 7.55	0.766
Concomitant cholecystectomy	59 (9.0%)	14 (10.6%)	0.621
Concomitant hiatal hernia repair	34 (5.2%)	7 (5.3%)	1.000
Postoperative leakage	3 (0.5%)	0 (0%)	1.000 ^a
30-day severe postoperative morbidity	3 (0.5%)	1 (0.8%)	1.000 ^a
<i>Postoperative endoscopic findings</i>			0.514 ^b
Normal endoscopy	503 (76.8%)	103 (78.0%)	
GERD ^c grade B*	109 (16.6%)	19 (14.4%)	0.552
Hiatal hernia	30 (4.6%)	7 (5.3%)	0.763
Constriction at the incisura angularis	13 (2.0%)	–	
Constriction at the ring	–	3 (2.3%)	
Conversion to RYGB	111 (16.9%)	0 (0%)	<0.0001

Categorical variables are expressed in counts (percentages). Continuous variables are expressed in median values (interquartile range)

^aFisher's exact test

^bMonte Carlo test

^aSG Sleeve gastrectomy, ^bBSG Banded sleeve gastrectomy

[†]Operative time represents the main surgery without additional procedures

^cGERD was assessed using endoscopic Los Angeles classification

Table 4 Postoperative laboratory work-up and impact on comorbidities

	SG ^a group (n = 655)	BSG ^b group (n = 132)	p
Hb ^c	12.5 (11.0–14.0)	12.5 (11.0–14.0)	0.834
Cholesterol	207 (170–260)	209 (170–260)	0.713
Triglycerides	178 (150–240)	178 (150–243)	0.969
Albumin	4.0 (3.6–4.6)	4.0 (3.6–4.6)	0.805
Ferritin	112 (79–187)	109 (76.5–175.5)	0.466
Vitamin D3	29 (24–38.2)	29 (25–38)	0.986
Vitamin B12	325 (214–532)	325 (214–536)	0.650
FBS ^d	95.0 (83.0–106.0)	96.0 (83.0–104.0)	0.847

Categorical variables are expressed in counts (percentages). Continuous variables are expressed in median values (interquartile range)

^aSG Sleeve gastrectomy

^bBSG Banded sleeve gastrectomy

^cHb hemoglobin; ^dFBS fasting blood sugar

role of gastric banding in activating the peripheral satiety pathway [26].

The initial %EWL at 6 months of follow-up in this study was statistically significantly lower in the BSG cohort than the SG cohort, but unclear if this has clinical relevance. We do not have a clear explanation for this issue. Still, many causes have been reported for impaired weight loss after bariatric surgery, including behavioral problems, physical inactivity, and hormonal factors [17]. The overall weight loss


Fig. 2 Bar chart comparing the impact of FBS in patients with diabetes before and after surgery in both study groups

Fig. 2 Bar chart comparing the impact of FBS in patients with diabetes before and after surgery in each study group

after surgery throughout the follow-up in this study is consistent with data published in the literature [25, 27–34]. The most logical thoughts are that a band can be positioned as an “extra” weight loss product, but more as an “anti”-weight regain product. The sleeve operation is primarily the reason why patients lose weight with the 70–80% gastric volume restriction of the stomach and that the ring will help after sufficient weight loss that the regain will be prevented. The literature shows equal initial weight loss between the BSG and the SG or better weight loss in the BSG [25, 27–31, 33, 34]. However, data from a randomized prospective study has



Fig. 3 Bar chart comparing the food tolerance at 1 and 4 years after surgery in each group




Fig. 4 Graph comparing EWL% between the groups over 4 years of follow-up

shown an initial lower %EBMIL in the BSG cohort compared to the SG cohort [32].

The food tolerance score in our study can explain the difference in weight loss, and weight regain between the study groups at different periods. The food tolerance was similar at the end of the first year in the groups, and this correlated with the equivalent %EWL at the same time. Meanwhile, food tolerance significantly increased at the end of the 4th year postoperatively in the SG group compared to a stable food tolerance in the BSG group at the same time, which correlated with the significantly higher rate of WR in the SG group at 4-year postoperatively than in the BSG group.

The incidence of vomiting after BSG was higher in the first 12 months when the meal volume and pouch dilatation proximal to the band increased [27]. We could not demonstrate similar findings regarding the incidence of vomiting. Food tolerance is still unfavorable among the patients that underwent BSG.

Although Alvarenga et al. have reported a %EWL of 86% at 1-year post SG, this rate dropped to 63% 5 years

postoperatively. This was partially attributed to the drop-out rate and the incomplete follow-up of some of their study participants [3]. Furthermore, Himpens et al. reported a low %EWL of 53% in the sixth-year post SG [24]. Bhandari et al. recently reported that the absolute weight loss was significantly higher at the start of the second year postoperatively in the BSG group than in the SG group [28]. Even though previous studies reported equivalent change in BMI at 6 and 12 months postoperatively, in our study, BSG was associated with a significantly lower EWL than non-banded SG (43% versus 45%; $p=0.037$) at 6 months postoperatively. Unlike other previous studies, our study showed similar operative time and length of hospital stay for the SG and BSG groups [28].

Regarding comorbidities, fasting blood glucose, serum cholesterol, and triglyceride levels were similar postoperatively in the study groups. In addition, patients with diabetes in the BSG group showed a more significant drop in their FBS level than those in the SG group. This refutes the previous unexplained findings (in the literature) of higher HbA1c and FBS levels in the BSG group than in the SG group [28]. Fink et al. have explained the reduction in the symptoms of regurgitation and reflux in patients in the BSG group by the reflux barrier effect of the ring [29]. This could explain the high rate of esophagitis remission after BSG in this study.

Three patients (2.3%) presented with ring site strictures during the postoperative follow-up visit. Those patients presented with solid dysphagia and persistent reflux symptoms, and the endoscopy revealed strictures at the site of the ring, which was not tight and was passable to the scope in all cases. We tried Pneumatic balloon dilation before considering the removal of the minimizer ring. We performed the dilatation using 20 mm pneumatic balloons inflated for one minute twice in the same session. The three patients responded well to the dilatation sessions and had improvement in their symptoms. The reason for the improvement of symptoms may be an improvement in the adaptation of the stomach with dilatation or even psychological relief. Some authors reported management of stenosis after BSG by increasing the band length to 7.5 cm or removal of the band due to dysphagia or severe reflux symptoms [6, 27, 30]. We apply the ring loosely around the gastric sleeve pouch at 7.5 cm in length from the start.

No band slippages nor erosions were detected. The occurrence of band erosions in BSG may be an extremely rare complication that was not reported by authors who addressed the BSG [25, 27, 31, 34]. Band slippage after BSG is also a rarely reported complication; it was reported by Fink et al. in one patient who was managed by removal of the band [30].

These results confirm the safety of the technique in the mid-term. Similarly, Gentileschi et al. reported no band-related complications over an extended follow-up period in a smaller cohort [32]. These results may be attributed to the

loose application of the ring (compared to the traditional gastric band), leading to fewer chances of gastric erosion and stricture; moreover, the limited dissection of the pars flaccida is responsible for the lower rate of ring slippage.

In this study, the conversion rate from SG to RYGB in the SG cohort was significantly higher than in the BSG cohort, 16.9% vs. 0%, respectively ($p < 0.001$). Conversion of LSG to another bariatric procedure is now a well-reported issue in the literature, ranging from 4.7% to 20.7%, reaching up to 40% in higher volume centers [4, 33]. RYGB is the most reported revision procedure after LSG in the literature (75.2%), followed by resleeve (18.7%) [33]. In our practice, we choose RYGB as a revisional procedure for patients with SG who have symptomatic grade “B” or more reflux esophagitis not responding to medical treatment or WR/insufficient weight loss with uniform dilatation of the gastric sleeve pouch without residual fundus or antrum. We adopt a re-sleeve only when the gastric sleeve pouch has residual fundus or antrum. When the gastric sleeve pouch is uniformly dilated, conversion to RYGB is the best option [4, 33].

The reported rates of revisional surgery after BSG are lower than SG in the literature, ranging from 2 to 5%, with the most common causes of conversion being band slippage and GERD. At the same time, the most performed procedures are removal of the band or increasing the band length and conversion to RYGB [6, 27, 30]. Also, the banded SG is also reported to have lower rates of GERD when compared to LSG [34]. In this study, we had similar findings regarding the incidence of GERD, which may be correlated to the band's presence that mechanically prevents the reflux of the gastric juice into the esophagus while the part of the stomach above the ring has few acid-secreting glands. Also, WR incidence in the BSG cohort was lower than in LSG. The causes of conversion in this study were WR (7.75%), GERD (6.5%), and combined GERD with WR (2.6%). The most-reported indication for conversion after LSG is the weight regain (70%), followed by GERD (16%) [4]. This coincides with our findings.

To the best of our knowledge, our study is one of the largest studies to date to evaluate the mid-term outcome of BSG; however, there are some limitations. First, the postoperative gastric volumetric studies were not included to compare the pouch dilatation between the groups. Second, the analysis of the resolution of the comorbidities in the study groups was incomplete. Third, routine endoscopy was only performed for all patients 1 year after surgery and was repeated later only for patients with symptoms. Some patients may have missed asymptomatic problems like GERD and Hiatal hernias or complications related to the band.

Finally, some of our initial SG participants were discarded after propensity score matching; however, these patients had initially refused to undergo BSG.

Conclusion

Although the %EWL achieved in the BSG group was low in the first year postoperatively, the mid-term (sustained) weight loss associated with BSG was superior to that associated with non-banded SG. BSG is a safe procedure with no significant mid-term band-related morbidities. The impact of BSG is equivalent and might be superior to that of SG in terms of resolution of comorbidities such as DM and GERD.

Funding Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). No funding source to declare.

Declarations

Disclosures Dr. Mohamed Hany, Dr. Ahmed Sabry, Dr. Bart Torensma, Dr. Khaled Ahmed, Dr. Mostafa Refaie, Dr. Ahmed Zidan, Dr. Ann Samy Shafiq Agayby, Dr. Mohamed Ibrahim, and Dr. Mohamed Mourad has no conflicts of interest or financial ties to disclose.

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent All the patients provided informed consent to undergo BSG or SG and use their data for research.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Buchwald H, Oien DM (2013) Metabolic/bariatric surgery worldwide 2011. *Obes Surg* 23:427–436
2. Angrisani L, Santonicola A, Iovino P, Formisano G, Buchwald H, Scopinaro N (2015) Bariatric surgery worldwide 2013. *Obes Surg* 25:1822–1832
3. Alvarenga ES, Lo Menzo E, Szomstein S, Rosenthal RJ (2016) Safety and efficacy of 1020 consecutive laparoscopic sleeve gastrectomies performed as a primary treatment modality for morbid obesity. A single-center experience from the metabolic and bariatric surgical accreditation quality and improvement program. *Surg Endosc* 30:2673–2678

4. Clapp B, Wynn M, Martyn C, Foster C, O'Dell M, Tyroch A (2018) Long term (7 or more years) outcomes of the sleeve gastrectomy: a meta-analysis. *Surg Obes Relat Dis* 14:741–747
5. Colpaert J, Van Nieuwenhove Y (2021) Novel techniques, same complications: slippage and erosion of a MiniMizer band after Banded laparoscopic Roux-En-Y gastric bypass. *Obes Surg* 31:4188–4190
6. Lemmens L, Van Den Bossche J, Zaveri H, Surve A (2018) Banded sleeve gastrectomy: better long-term results? A long-term cohort study until 5 years follow-up in obese and superobese patients. *Obes Surg* 28:2687–2695
7. O'Brien PE, McPhail T, Chaston TB, Dixon JB (2006) Systematic review of medium-term weight loss after bariatric operations. *Obes Surg* 16:1032–1040
8. Greenstein AJ, Jacob BP (2008) Placement of a laparoscopic adjustable gastric band after failed sleeve gastrectomy. *Surg Obes Relat Dis* 4:556–558
9. Arceo-Olaiz R, Espana-Gomez MN, Montalvo-Hernandez J, Velazquez-Fernandez D, Pantoja JP, Herrera MF (2008) Maximal weight loss after banded and unbanded laparoscopic Roux-en-Y gastric bypass: a randomized controlled trial. *Surg Obes Relat Dis* 4:507–511
10. Aarts EO, Dogan K, Koehestanie P, Aufenacker TJ, Janssen IM, Berends FJ (2014) Long-term results after laparoscopic adjustable gastric banding: a mean fourteen-year follow-up study. *Surg Obes Relat Dis* 10:633–640
11. Kowalewski PK, Olszewski R, Kwiatkowski A, Galazka-Swiderek N, Cichon K, Pasnik K (2017) Life with a gastric band. long-term outcomes of laparoscopic adjustable gastric banding—a retrospective study. *Obes Surg* 27:1250–1253
12. Buchwald H, Consensus Conference P (2005) Consensus conference statement bariatric surgery for morbid obesity: health implications for patients, health professionals, and third-party payers. *Surg Obes Relat Dis* 1:371–381
13. NIH conference (1991) Gastrointestinal surgery for severe obesity. consensus development conference panel. *Ann Intern Med* 115:956–961
14. Suter M, Calmes JM, Paroz A, Giusti V (2007) A new questionnaire for quick assessment of food tolerance after bariatric surgery. *Obes Surg* 17:2–8
15. Wang X, Chang XS, Gao L, Zheng CZ, Zhao X, Yin K, Fang GE (2016) Effectiveness of laparoscopic sleeve gastrectomy for weight loss and obesity-associated co-morbidities: a 3-year outcome from Mainland Chinese patients. *Surg Obes Relat Dis* 12:1305–1311
16. Nedelcu M, Khwaja HA, Rogula TG (2016) Weight regain after bariatric surgery—how should it be defined? *Surg Obes Relat Dis* 12:1129–1130
17. De Raaff CAL, Coblijn UK, de Vries N et al (2016) Predictive factors for insufficient weight loss after bariatric surgery: does obstructive sleep apnea influence weight loss? *Obes Surg* 26:1048–1056
18. King WC, Hinerman AS, Belle SH, Wahed AS, Courcoulas AP (2018) Comparison of the performance of common measures of weight regain after bariatric surgery for association with clinical outcomes. *JAMA* 320:1560–1569
19. da Silva FB, Gomes DL, de Carvalho KM (2016) Poor diet quality and postoperative time are independent risk factors for weight regain after Roux-en-Y gastric bypass. *Nutrition* 32:1250–1253
20. Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 240:205–213
21. Altman DG (1990) Practical statistics for medical research. CRC Press, Cham
22. Haukoos JS, Lewis RJ (2015) The propensity score. *JAMA* 314:1637–1638
23. Gautier T, Sarcher T, Contival N, Le Roux Y, Alves A (2013) Indications and mid-term results of conversion from sleeve gastrectomy to Roux-en-Y gastric bypass. *Obes Surg* 23:212–215
24. Himpens J, Dobbeleir J, Peeters G (2010) Long-term results of laparoscopic sleeve gastrectomy for obesity. *Ann Surg* 252:319–324
25. Tognoni V, Benavoli D, Bianciardi E, Perrone F, Ippoliti S, Gaspari A, Gentileschi P (2016) Laparoscopic sleeve gastrectomy versus laparoscopic banded sleeve gastrectomy: first prospective pilot randomized study. *Gastroenterol Res Pract* 2016:6419603
26. Burton PR, Brown WA (2011) The mechanism of weight loss with laparoscopic adjustable gastric banding: induction of satiety not restriction. *Int J Obes (Lond)* 35:S26–30
27. Karcz WK, Karcz-Socha I, Marjanovic G, Kuesters S, Goos M, Hopt UT, Szewczyk T, Baumann T, Grueneberger JM (2014) To band or not to band—early results of banded sleeve gastrectomy. *Obes Surg* 24:660–665
28. Bhandari M, Mathur W, Kosta S, Mishra AK, Cummings DE (2019) Banded versus unbanded laparoscopic sleeve gastrectomy: 5-year outcomes. *Surg Obes Relat Dis* 15:1431–1438
29. Fink JM, Hetzenecker A, Seifert G, Runkel M, Laessle C, Fichtner-Feigl S, Marjanovic G (2020) Banded versus nonbanded sleeve gastrectomy: a randomized controlled trial with 3 years of follow-up. *Ann Surg* 272:690–695
30. Fink JM, von Pigenot A, Seifert G, Laessle C, Fichtner-Feigl S, Marjanovic G (2019) Banded versus nonbanded sleeve gastrectomy: 5-year results of a matched-pair analysis. *Surg Obes Relat Dis* 15(8):1233–1238
31. Soliman AMS, Lasheen M (2015) Effect of banded laparoscopic sleeve gastrectomy on weight loss maintenance: comparative study between banded and non-banded sleeve on weight loss. *Bariatric Surg Pract Patient Care* 10(3):99–104
32. Gentileschi P, Bianciardi E, Siragusa L, Tognoni V, Benavoli D, D'Ugo S (2020) Banded sleeve gastrectomy improves weight loss compared to nonbanded sleeve: midterm results from a prospective randomized study. *J Obes* 2020:9792518
33. Lazzati A, Bechet S, Jouma S, Paolino L, Jung C (2020) Revision surgery after sleeve gastrectomy: a nationwide study with ten years of follow-up. *Surg Obes Relat Dis* 16(10):1497–1504
34. Fink JM et al (2017) Banding the sleeve improves weight loss in midterm follow-up. *Obes Surg* 4:1098–1103

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.